StockDrifts LogoStockDrifts

Pharos iBio 388870

Company
파로스아이바이오Pharos iBio
Insiders
2
Buys
4
Total Value
₩316M ($220K)
Avg Return
+22.26%
Last Filing
2026-06-04

Pharos iBio (388870) has 4 disclosed insider purchases and 0 disclosed disposals on record, filed by 2 distinct insiders. Together those filings cover ₩316M ($220K) in reported transaction value. The earliest filing StockDrifts holds for Pharos iBio is dated 2024-09-27; the most recent is 2026-06-04. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is +22.26%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2026-06-04BUYMarket Buy
윤정혁
Jeonghyeok Yoon
CEO15.0K₩6,300+24.1%₩95M ($66K)
2026-01-09SELL임원퇴임
HAN HYE JUNG
president-240.0K₩10,350+20.3%₩2.5B ($1.7M)
2025-07-16BUYMarket Buy
김규태
Kim Gyu-tae
vice president12.5K₩6,230+32.4%₩78M ($54K)
2025-07-14BUYMarket Buy
윤정혁
Jeonghyeok Yoon
CEO8.3K₩5,910+39.6%₩49M ($34K)
2024-09-27BUYMarket Buy
윤정혁
Jeonghyeok Yoon
CEO10.7K₩8,880-7.1%₩95M ($66K)

Frequently asked questions

Who has been buying Pharos iBio stock?
2 distinct insiders have filed 4 disclosed insider purchases in Pharos iBio (388870), most recently on 2026-06-04. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Pharos iBio have?
Pharos iBio has 4 buy-side and 0 sell-side disclosures on record, covering ₩316M ($220K) in total reported value, spanning 2024-09-27 to 2026-06-04.
Where does StockDrifts get Pharos iBio insider data?
From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Pharos iBio. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.